The Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to MedetomidineThe Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to Medetomidine
Addiction Medicine: Beyond the Abstract
Dr G. Marie Perrone discusses how metatomidine has entered the fentanyl supply, changing withdrawal presentations and treatment strategies for clinicians. The conversation highlights clinical clues, management approaches with alpha agonists, and the importance of public health collaboration and stronger addiction medicine education.
18:20•7 Aug 2026
From Xylazine to Metatomidine: A New Challenge in Fentanyl Adulterants
Episode Overview
- Metatomidine in the fentanyl supply is significantly more potent than xylazine and produces a distinct, severe withdrawal syndrome with marked autonomic symptoms.
- Key clinical clues for metatomidine withdrawal include early onset after last use, abnormal vital signs, tremors, nausea and vomiting, without classic opioid signs like gooseflesh and diarrhoea.
- There is no widely available laboratory test or standard of care, so clinicians must rely on symptom patterns, local drug-checking data and careful therapeutic trials.
- Alpha agonists such as clonidine, tizanidine and guanfacine form the backbone of management, with dexmedetomidine reserved for more severe cases despite increasing dose requirements.
- Strengthening collaboration between hospitals, addiction teams and public health agencies, plus expanding addiction teaching in medical schools, is crucial to respond to emerging adulterants.
“Metatomidine has changed everything. It is 10 to, you know, 20 times more potent than xylazine.”
How do different strategies aid in addiction recovery? This conversation on Addiction Medicine: Beyond the Abstract zooms in on a very specific, and frankly alarming, shift in the drug supply: “the shifting landscape of a fentanyl adulterant, moving from xylazine to metatomidine.” Host Shawn McNeil, MD talks with addiction toxicologist G. Marie Perrone, MD about how metatomidine has started turning up alongside fentanyl in Philadelphia and beyond, and what that means for clinicians on the ground.
The tone stays relaxed and conversational, but the content is squarely aimed at clinicians, researchers, and anyone who wants to understand how fast the opioid crisis keeps changing. Dr Perrone walks through her path from emergency medicine and medical toxicology into addiction medicine, explaining how seeing colleagues build addiction consult teams – and witnessing “patient interactions and success and turnarounds” – drew her into the field.
From there, the discussion gets very practical: how buprenorphine changed care in the heroin era, how fentanyl and then xylazine complicated withdrawal, and why “metatomidine has changed everything. It is 10 to, you know, 20 times more potent than xylazine.” You’ll hear clear descriptions of how metatomidine withdrawal differs from opioid withdrawal – no gooseflesh or diarrhoea, but intense autonomic symptoms, tremors, vomiting and very abnormal vital signs – and why there’s still no definitive test or standard of care.
Dr Perrone shares real-world strategies using alpha agonists such as clonidine, tizanidine and guanfacine, and why some patients ultimately require dexmedetomidine in intensive care. The episode also widens out to public health, highlighting how the Philadelphia Department of Public Health coordinated monthly calls to compare cases and drug-checking data, and ends with advice for future addiction medicine clinicians and a call to strengthen addiction teaching in medical schools.
If you work with people who use opioids – or you’re just trying to keep up with a fast-moving crisis – this one gives plenty to think about.
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.